SouthPaw: A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) in Heart Failure with Preserved Ejection Fraction (HFpEF)
This Study is
No Longer Enrolling
This is a 24 week study to evaluate the safety of using oral treprostinil to treat PH associated with HFpEF
Adult
must be 18 - 79 years, have a diagnosis of PH associated with HFpEF, and not be on any medications to treat Pulmonary Hypertension. (Oxygen, diuretics and anti- coagulation meds are OK).
III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.
Supportive Care
National
University of Colorado Hospital
Protocol Number: 17-0163
More information available at ClinicalTrials.gov: NCT03037580
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers